 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C27H29IN2O4 |
| Molar mass | 572.443 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
IBNtxA, or3-iodobenzoyl naltrexamine, is an atypicalopioidanalgesic drug derived fromnaltrexone. In animal studies it produces potent analgesic effects that are blocked bylevallorphan[1] and so appear to beμ-opioid mediated, but it fails to produceconstipation orrespiratory depression, and is neither rewarding or aversive[2] inconditioned place preference protocols.[3] These unusual properties are thought to result from agonist action at asplice variant orheterodimer of the μ-opioid receptor,[4] rather than at the classical full length form targeted by conventional opioid drugs.[5]
In the Radioligand binding assay it has shown to have affinities of 0.11nM at the MOR, 0.24nM at the DOR and 0.03nM at the KOR and in the Hot- Plate Assay it is shown to be around 20x more potent thanmorphine. Azido Aryl Analogues of IBNtxA retain significant activity at the MOR.[6]
